< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research

< em > Correction to: < /em > Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. < em > J. Ocul. Pharmacol. Ther < /em > 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160
J Ocul Pharmacol Ther. 2023 Jun;39(5):359. doi: 10.1089/jop.2022.0160.correx.NO ABSTRACTPMID:37310367 | DOI:10.1089/jop.2022.0160.correx (Source: JOP)
Source: JOP - June 13, 2023 Category: Gastroenterology Source Type: research